Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.8K
Overview
51.8K
Metallic Solids02:37

Metallic Solids

20.8K
Metallic solids such as crystals of copper, aluminum, and iron are formed by metal atoms. The structure of metallic crystals is often described as a uniform distribution of atomic nuclei within a “sea” of delocalized electrons. The atoms within such a metallic solid are held together by a unique force known as metallic bonding that gives rise to many useful and varied bulk properties.
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
20.8K
Structures of Solids02:22

Structures of Solids

18.0K
Solids in which the atoms, ions, or molecules are arranged in a definite repeating pattern are known as crystalline solids. Metals and ionic compounds typically form ordered, crystalline solids. A crystalline solid has a precise melting temperature because each atom or molecule of the same type is held in place with the same forces or energy. Amorphous solids or non-crystalline solids (or, sometimes, glasses) which lack an ordered internal structure and are randomly arranged. Substances that...
18.0K
Network Covalent Solids02:18

Network Covalent Solids

16.2K
Network covalent solids contain a three-dimensional network of covalently bonded atoms as found in the crystal structures of nonmetals like diamond, graphite, silicon, and some covalent compounds, such as silicon dioxide (sand) and silicon carbide (carborundum, the abrasive on sandpaper). Many minerals have networks of covalent bonds.
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
16.2K
Molecular and Ionic Solids02:54

Molecular and Ionic Solids

20.2K
Crystalline solids are divided into four types: molecular, ionic, metallic, and covalent network based on the type of constituent units and their interparticle interactions.
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
20.2K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kaposi's Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series.

Cancers·2024
Same author

Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe.

JAMA network open·2024
Same author

Thirty-two-year trends of cancer incidence by sex and cancer site in the Veneto Region from 1987 to 2019.

Frontiers in public health·2024
Same author

Highly biocompatible material for enhanced abdominal wall repair: a retrospective study with EGIS<sup>®</sup> porcine dermal matrix.

Case reports in plastic surgery & hand surgery·2024
Same author

Gender Differences in Soft Tissue and Bone Sarcoma: A Narrative Review.

Cancers·2024
Same author

Desmoid Tumors in the Active Surveillance Era: Evaluation of Treatment Options and Pain Relief in a Single-Center Retrospective Analysis.

Journal of personalized medicine·2023
Same journal

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Oncology·2026
Same journal

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026
Same journal

Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology.

The Lancet. Oncology·2026
Same journal

European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.

The Lancet. Oncology·2026
Same journal

Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases.

The Lancet. Oncology·2026
Same journal

Correction to Lancet Oncol 2025; 26: e369-80.

The Lancet. Oncology·2026
See all related articles

Related Experiment Video

Updated: Feb 8, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K

Part I: Vaccines for solid tumours.

Simone Mocellin1, Susanna Mandruzzato, Vincenzo Bronte

  • 1Department of Oncological and Surgical Sciences, University of Padova, Italy. mocellins@hotmail.com <mocellins@hotmail.com>

The Lancet. Oncology
|November 4, 2004
PubMed
Summary
This summary is machine-generated.

Active specific immunotherapy, a promising cancer treatment, shows potential through vaccination strategies. Further research into tumor immunology is crucial for developing next-generation cancer vaccines.

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K
Electrochemotherapy of Tumours
03:57

Electrochemotherapy of Tumours

Published on: December 14, 2008

25.1K

Related Experiment Videos

Last Updated: Feb 8, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.8K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K
Electrochemotherapy of Tumours
03:57

Electrochemotherapy of Tumours

Published on: December 14, 2008

25.1K

Area of Science:

  • Oncology
  • Immunology
  • Biotherapy

Background:

  • Active specific immunotherapy is a developing therapeutic strategy for cancer treatment.
  • Preclinical and clinical studies demonstrate the immune system's ability to target malignant cells via vaccination.
  • Current anticancer vaccines are limited to clinical trials, necessitating further investigation.

Purpose of the Study:

  • To review cancer vaccine strategies used in clinical settings.
  • To analyze results from over 200 clinical trials conducted in the last two decades.
  • To discuss preclinical tumor immunology insights for future vaccine design.

Main Methods:

  • Literature review of clinical trials on cancer vaccines.
  • Analysis of published data from over 200 clinical trials.
  • Synthesis of preclinical tumor immunology findings.

Main Results:

  • Summary of implemented cancer vaccine strategies.
  • Compilation of outcomes from extensive clinical trials.
  • Identification of immunological insights from animal and human studies.

Conclusions:

  • Active specific immunotherapy warrants continued investigation for cancer treatment.
  • Tumor response and immunological data support further research in cancer vaccines.
  • Preclinical insights can guide the development of advanced cancer vaccine generations.